JNJ0966 is primarily used in scientific research for its ability to selectively inhibit the deubiquitinase enzyme USP1. This inhibition plays a key role in disrupting DNA repair pathways, particularly in cancer cells that rely on the USP1-UAF1 complex for survival. Due to this mechanism, JNJ0966 is investigated as a potential therapeutic agent in oncology, especially in combination with DNA-damaging agents like chemotherapy or PARP inhibitors. It shows promise in enhancing the sensitivity of tumor cells to these treatments, making it a valuable tool in developing targeted cancer therapies. Its application is currently limited to preclinical studies, where it helps elucidate the role of USP1 in cellular processes and cancer progression.